Calypso Enters into Agreement to Be Acquired by Novartis

09-Jan-2024 - Calypso Biotech BV, a leader in the development of Interleukin15 (IL-15) targeted therapies, announced that it has entered into an agreement to be acquired by Novartis AG. Calypso’s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development ...

BASF strengthens its global production footprint for enzymes

BASF will invest at Novartis’ Kundl/Schaftenau Campus, in Austria

05-May-2021 - On April 26, 2021 BASF has agreed with Sandoz GmbH, a subsidiary of Novartis, to invest at the Kundl/Schaftenau Campus in Austria. This agreement enables BASF to further develop its production footprint for enzymes and biotechnology products. Both parties agreed not to disclose financial details ...

CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

Anticipated production of up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022 at the Novartis’ manufacturing site in Kundl, Austria

05-Mar-2021 - CureVac N.V. and Novartis AG announced that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway. Following final agreement, Novartis plans to ...

Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe

29-Jul-2020 - Sandoz, the Novartis generics and biosimilars division, is pleased to announce plans for a joint investment, together with the Austrian federal government, to strengthen the long-term future of integrated antibiotics manufacturing in Europe. Sandoz CEO Richard Saynor said: “This plan is a great ...

Novartis to invest $75 million in start-up Poseida

Poseida Therapeutics Raises $142 Million in Series C Financing

25-Apr-2019 - Poseida Therapeutics Inc. announced closing of a Series C financing round, raising $142 million led by a $75 million equity investment from Novartis Pharma AG, and joined by several new investors including Aisling Capital Management, Pentwater Capital Management, Perceptive Advisors as well as ...

Novartis announces change in Sandoz leadership

14-Mar-2019 - Novartis announced that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis on March 31, 2019. Francesco Balestrieri, currently Region Head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to ...

Fraunhofer IZI and Novartis Continue Collaboration with CAR-T Cell Therapy

03-Sep-2018 - Novartis and Fraunhofer IZI announced that a further agreement has been concluded between Novartis and the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig for the manufacture of the CAR (chimeric antigen receptor)-T cell therapy for patients in Europe over the next few years. The ...

Novartis to sell stake in consumer healthcare joint venture to GSK

Focussing on strategic priorities

27-Mar-2018 - Novartis announced that it has entered into an agreement with GlaxoSmithKline plc (GSK) to divest its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for USD13.0 billion. The sale will enable Novartis to further focus on the development and growth of its core ...

Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis

20-Mar-2018 - The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have access to commercially develop their therapeutic, biomaterial-based, cancer vaccine technology ...

Spinifex to be acquired by Novartis

Australian pain drug innovation company sold to Novartis for US$200m plus milestone payments

02-Jul-2015 - Spinifex Pharmaceuticals, Inc. and its Australian subsidiary Spinifex Pharmaceuticals Pty Ltd, a company focused on the development of new drugs for the treatment of chronic pain, announced agreement to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 ...